Please use this identifier to cite or link to this item: https://hdl.handle.net/10356/164428
Title: Toward precision phenotyping of multiple sclerosis
Authors: Pitt, David
Lo, Chih Hung
Gauthier, Susan A.
Hickman, Richard A.
Longbrake, Erin
Airas, Laura M.
Mao-Draayer, Yang
Riley, Claire
De Jager, Philip Lawrence
Wesley, Sarah
Boster, Aaron
Topalli, Ilir
Bagnato, Francesca
Mansoor, Mohammad
Stuve, Olaf
Kister, Ilya
Pelletier, Daniel
Stathopoulos, Panos
Dutta, Ranjan
Lincoln, Matthew R.
Keywords: Science::Medicine
Issue Date: 2022
Source: Pitt, D., Lo, C. H., Gauthier, S. A., Hickman, R. A., Longbrake, E., Airas, L. M., Mao-Draayer, Y., Riley, C., De Jager, P. L., Wesley, S., Boster, A., Topalli, I., Bagnato, F., Mansoor, M., Stuve, O., Kister, I., Pelletier, D., Stathopoulos, P., Dutta, R. & Lincoln, M. R. (2022). Toward precision phenotyping of multiple sclerosis. Neurology® Neuroimmunology & Neuroinflammation, 9(6), e200025-. https://dx.doi.org/10.1212/NXI.0000000000200025
Journal: Neurology® Neuroimmunology & Neuroinflammation
Abstract: The classification of multiple sclerosis (MS) has been established by Lublin in 1996 and revised in 2013. The revision includes clinically isolated syndrome, relapsing-remitting, primary progressive and secondary progressive MS, and has added activity (i.e., formation of white matter lesions or clinical relapses) as a qualifier. This allows for the distinction between active and nonactive progression, which has been shown to be of clinical importance. We propose that a logical extension of this classification is the incorporation of additional key pathological processes, such as chronic perilesional inflammation, neuroaxonal degeneration, and remyelination. This will distinguish MS phenotypes that may present as clinically identical but are driven by different combinations of pathological processes. A more precise description of MS phenotypes will improve prognostication and personalized care as well as clinical trial design. Thus, our proposal provides an expanded framework for conceptualizing MS and for guiding development of biomarkers for monitoring activity along the main pathological axes in MS.
URI: https://hdl.handle.net/10356/164428
ISSN: 2332-7812
DOI: 10.1212/NXI.0000000000200025
Schools: Lee Kong Chian School of Medicine (LKCMedicine) 
Rights: © 2022 The Author(s). Published by Wolters Kluwer Health, Inc. on behalf of the American Academy of Neurology. This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives License 4.0 (CC BY-NC-ND), which permits downloading and sharing the work provided it is properly cited. The work cannot be changed in any way or used commercially without permission from the journal.
Fulltext Permission: open
Fulltext Availability: With Fulltext
Appears in Collections:LKCMedicine Journal Articles

Files in This Item:
File Description SizeFormat 
e200025.full.pdf437.45 kBAdobe PDFThumbnail
View/Open

SCOPUSTM   
Citations 20

27
Updated on Jul 15, 2024

Web of ScienceTM
Citations 20

9
Updated on Oct 31, 2023

Page view(s)

83
Updated on Jul 13, 2024

Download(s) 50

59
Updated on Jul 13, 2024

Google ScholarTM

Check

Altmetric


Plumx

Items in DR-NTU are protected by copyright, with all rights reserved, unless otherwise indicated.